These newly discovered regulatory networks involving SNHG1 may serve as valuable targets for overcoming resistance to systemic therapy in HCC, and targeting SNHG1 can represent a pivotal strategy in personalizing HCC treatment. The gene discussed is SNHG1; the disease is hepatocellular carcinoma.